Bristol-Myers enters agreement with uniQure

Bristol-Myers Squibb Co. (NYSE: BMY) entered an exclusive strategic collaboration with uniQure N.V. (Nasdaq: QURE) to develop gene therapies for cardiovascular diseases. Shares of Bristol-Myers slipped 23 cents to close at $63.00 while uniQure stock leaped $10.75 to close at $33.61.